Clinical trials: Heparin
Haemodialysis
Efficacy and Local Tolerability of Topically Applied Heparin on the Suitability of Newly Constructed Primary Arteriovenous Fistulas in Patients Planned for Haemodialysis
The primary objective of this study is to evaluate the effect of topically applied heparin in comparison to placebo on suitability of newly constructed primary arteriovenous fistulas in patients planned for haemodialysis at 7th…
- Trial name
- NCT01382888
- Testing
- Heparin 2,400 IU /ml Cutaneous Spray
- Where
- 3 sites in Austria
- Volunteers
- 30 people
- Sponsor
- Cyathus Exquirere Pharmaforschungsgmbh
Healthy
Effects of LMWH in Healthy Subjects Treated With TB-402 and Effects of TB-402 in Healthy Subjects Treated With Warfarin
Administration of LMWH in healthy male subjects treated with TB-402 and administration of TB-402 in healthy male subjects treated with warfarin
- Trial name
- NCT00618579
- Testing
- LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects
- Where
- Denmark
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- ThromboGenics
Venous Thromboembolism, Deep Vein Thrombosis (DVT)
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism
- Trial name
- NCT00986154
- Testing
- edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin
- Where
- 454 sites in United States, Argentina and 36 more
- Volunteers
- 8,292 people
- Sponsor
- Daiichi Sankyo
Angina, Unstable, Myocardial Infarction
Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome
To compare efficacy and safety of dalteparin compared to unfractionated heparin in patients of non ST elevation acute coronary syndromes who are planned to undergo coronary interventions (angioplasty or bypass surgery)
- Trial name
- NCT00435487
- Testing
- Dalteparin ( Fragmin), Unfractionated heparin
- Where
- 8 sites in India
- Volunteers
- 173 people
- Sponsor
- Pfizer
Chronic Renal Failure
Safe Use of Heparin Sodium in Patients With Chronic Renal Failure.
The Heparin form a complex with a plasma protein, antithrombin III (ATIII), which is an endogenous anticoagulant. This complex inhibits the formation of thrombin and accelerates its destruction.
- Trial name
- Heparin (NCT01229072)
- Testing
- Heparin sodic, heparin liquemine
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Azidus Brasil
Angioplasty, Transluminal, Percutaneous Coronary
The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention
The objective of this dose-ranging study is to determine the effects of several intravenous (IV) regimens of otamixaban on pharmacodynamic markers (including markers of thrombosis and coagulation markers), safety/tolerability…
- Trial name
- SEPIA-PCI (NCT00133731)
- Testing
- Otamixaban (XRP0673), Unfractionated Heparin, Percutaneous Coronary Intervention
- Where
- 89 sites in United States, Belgium and 8 more
- Volunteers
- 947 people
- Sponsor
- Sanofi
Metastatic Pancreatic Cancer
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
People with primary metastatic pancreatic cancer will be treated with nab-paclitaxel and gemcitabine in combination with an investigational agent called necuparanib (M402).
- Trial name
- NCT01621243
- Testing
- nab-paclitaxel, gemcitabine, Necuparanib
- Where
- 37 sites in United States, Canada
- Volunteers
- 128 people
- Sponsor
- Momenta Pharmaceuticals, Inc.
Venous Thromboembolism
Xarelto Regulatory Post-Marketing Surveillance
This study is to identify the following problems and questions with respect to the safety and effectiveness of Xarelto in comparison with other pharmacologic agents in the prophylaxis of venous thromboembolism (VTE) in a large…
- Trial name
- NCT01029743
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)
- Where
- South Korea
- Volunteers
- 3,388 people
- Sponsor
- Bayer
Thrombosis
Etude (Study) Phase I Enox - UnFractionated Heparin (UFH)
Primary objective: to characterize the pharmacokinetic and the pharmacodynamic profile after intravenous bolus injection of unfractionated heparin (UFH) after repeated sc 100 IU anti-Xa/kg (corresponding to 1 mg/kg) twice a day…
- Trial name
- NCT00622115
- Testing
- Enoxaparin
- Where
- France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Sanofi
Acute Myocardial Infarction
Bivalirudin in Acute Myocardial Infarction
The purpose of the study is to evaluate the efficacy and safety of bivalirudin in AMI patients with DES. This is a prospective, randomized, single-blind, active drug controlled multicenter clinical research and the study would…
- Trial name
- NCT02897037
- Testing
- Bivalirudin, heparin
- Where
- China
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Peripheral Vascular Diseases
GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)
The objective of the study is collect data on the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface in the treatment of chronic Superficial Femoral Artery disease. Device patency at 12 months is the primary endpoint.
- Trial name
- VIPER (NCT00541307)
- Testing
- Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
- Where
- 5 sites in United States
- Volunteers
- 119 people
- Sponsor
- W.L.Gore & Associates
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery
The primary objective was to compare the efficacy of once daily [q.d.] subcutaneous [s.c.] injections of Semuloparin sodium (AVE5026) with q.d. s.c.
- Trial name
- SAVE-HIP1 (NCT00697099)
- Testing
- Semuloparin sodium, Enoxaparin sodium
- Where
- 30 sites in United States, Argentina and 28 more
- Volunteers
- 2,326 people
- Sponsor
- Sanofi
Venous Thromboembolism
Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany
Researcher in this study want to compare the effectiveness of Rivaroxaban (Xarelto) versus low-molecular-weight heparin (LMWH) and phenprocoumon for the treatment and secondary prevention of venous thromboembolism by evaluating…
- Trial name
- NCT04444804
- Testing
- Rivaroxaban (Xarelto, BAY 59-7939), LMWH and Phenprocoumon
- Where
- Germany
- Volunteers
- 22,153 people
- Sponsor
- Bayer
Coronary Artery Disease, Angina, Unstable
Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)
This is a phase II multi-centre study in 140 patients undergoing elective PCI to obtain the information on dose-response of argatroban in pharmacodynamic markers and to assess the anticoagulation, safety and efficacy of…
- Trial name
- NCT00508924
- Testing
- Argatroban, Heparin
- Where
- 8 sites in Belgium, Germany
- Volunteers
- 140 people
- Sponsor
- Tanabe Pharma Corporation
Type 1 Diabetes Mellitus
Heparinized Islets in Clinical Islet Transplantation
In this study the islets will be surface modified to carry immobilised heparin (Corline Heparin Conjugate) prior to transplantation.
- Trial name
- NCT00678990
- Testing
- Transplantation of islets with heparin coating
- Where
- 2 sites in Sweden
- Volunteers
- 10 people
- Sponsor
- Corline Biomedical AB
Chronic Kidney Disease, Patients Requiring Heparin Free Dialysis Treatments
HepZero:Heparin Free Dialysis With Evodial
The study hypothesis is that with Evodial in patients requiring heparin free dialysis, the heparin free treatment can be performed easily (without saline flushes or blood predilution) and is at least not inferior and maybe…
- Trial name
- NCT01318486
- Testing
- Heparin free dialysis technique, Evodial
- Where
- 10 sites in Belgium, Canada and 5 more
- Volunteers
- 265 people
- Sponsor
- Vantive Health LLC
Healthy
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin
Normal subjects will receive unfractionated heparin followed by a single dose of PER977 with dose escalation by cohort. Ten subjects enrolled in Cohort 4 will receive a single dose of PER977 followed by a one-week washout and…
- Trial name
- NCT02206087
- Testing
- PER977, Heparin Sodium
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Cancer, Venous Thromboembolism
CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)
The aim of the study is to evaluate the efficacy and safety of Bemiparin, a second-generation LMWH, in the prophylaxis of VTE (using a postoperative regimen, i.e.
- Trial name
- NCT00219973
- Testing
- Bemiparin
- Where
- 4 sites in Portugal, Romania and 2 more
- Volunteers
- 526 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Advanced Cancer, Metastatic Cancer
Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)
In this phase III, multicenter study, 1200 patients with lung, breast, gastrointestinal (stomach, colon-rectum, pancreas), ovarian or head and neck cancer undergoing chemotherapy will be randomly assigned (at the beginning of…
- Trial name
- NCT00951574
- Testing
- Nadroparin calcium
- Where
- 46 sites in Italy
- Volunteers
- 1,166 people
- Sponsor
- Italfarmaco
Dialysis Catheter Infections
Efficacy Study to Evaluate B-Lock™ as an Antimicrobial Lock Solution in Dialysis Patients With a CVC
Hypothesis: B-Lock is a safe and effective catheter lock solution that will maintain catheter patency and reduce Central Line Associated Blood Stream Infections (CLABSI) in dialysis patients using a central venous catheter (CVC)…
- Trial name
- NCT01989091
- Testing
- B-Lock, Heparin 5,000 U/mL
- Where
- 21 sites in Hungary, Poland
- Volunteers
- 270 people
- Sponsor
- Great Lakes Pharmaceuticals Inc.